These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34422904)

  • 1. Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis.
    Zimu Z; Jia Z; Xian F; Rui M; Yuting R; Yuan W; Tianhong W; Mian M; Yinlong L; Enfang S
    Front Mol Biosci; 2021; 8():696072. PubMed ID: 34422904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    Shan E; Cao YN; Zhang Y; Chen W; Ren X; Zhu S; Xi X; Mu S; Ma M; Zhi T; Li X
    BMC Cancer; 2023 Sep; 23(1):846. PubMed ID: 37697240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
    Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
    Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
    Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
    J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of
    Ji X; Chen X; Lin G; Ma K; Yang J; Zhao X; Chen S; Yang J
    Front Cell Neurosci; 2024; 18():1440409. PubMed ID: 39360264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
    Zhang W; Liu Z; Liu B; Jiang M; Yan S; Han X; Shen H; Na M; Wang Y; Ren Z; Liu B; Jiang Z; Gao Y; Lin Z
    Cancer Cell Int; 2021 Jun; 21(1):297. PubMed ID: 34098960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between chromosome 1p/19q status and VEGF mRNA expression in gliomas.
    Yang B; Hao XQ; Zeng XW; Ji TL; Pan S; Feng YG
    Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas.
    Yang B; Pan YB; Ma YB; Chu SH
    Front Oncol; 2020; 10():250. PubMed ID: 32257943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Panel of Synapse-Related Genes as a Biomarker for Gliomas.
    Ji X; Zhang H; Cui Q
    Front Neurosci; 2020; 14():822. PubMed ID: 32848578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma.
    Zhang C; Yu R; Li Z; Song H; Zang D; Deng M; Fan Y; Liu Y; Zhang Y; Qu X
    Cancer Manag Res; 2019; 11():4971-4984. PubMed ID: 31213913
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.
    Wang P; Wu M; Tu Z; Tao C; Hu Q; Li K; Zhu X; Huang K
    Front Oncol; 2020; 10():1119. PubMed ID: 32974125
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q.
    Zou H; Li C; Wanggou S; Li X
    J Cancer; 2020; 11(15):4297-4307. PubMed ID: 32489448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.